After Cowen & Co. and H.C. Wainwright gave Seres Therapeutics (NASDAQ: MCRB) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Matthew Lillis reiterated a Buy rating on Seres Therapeutics today and set a price target of $13. The company’s shares closed yesterday at $6.12.
Lillis noted:
“: We reiterate our Overweight rating and are adjusting our price target to $13 from $15. We believe Seres is at the forefront of unlocking the potential for microbiome modulation to generate novel methods by which to treat medical conditions. In our view, the company’s re-prioritization may yield the progress necessary for MCRB stock to recover and provide unequivocal clinical evidence that microbiome-based experimental therapies demonstrate a desired effect.”
According to TipRanks.com, Lillis is a 1-star analyst with an average return of -1.5% and a 37.5% success rate. Lillis covers the Healthcare sector, focusing on stocks such as Taiwan Liposome Company Ltd, Supernus Pharmaceuticals, and Evofem Biosciences Inc.
Currently, the analyst consensus on Seres Therapeutics is a Strong Buy with an average price target of $14.60, a 138.6% upside from current levels. In a report issued on February 22, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $16 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.02 and a one-year low of $4.42. Currently, Seres Therapeutics has an average volume of 114K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seres Therapeutics, Inc. is a microbiome therapeutics platform company, which engages in the development of biological drugs. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
